TY - JOUR AU - Hoffmann, Sarah; Meisel, Andreas TI - Escalation Strategies in the Treatment of Refractory Myasthenia Gravis SN - 2511-1795 PY - 2018 JF - Neurology International Open LA - EN VL - 02 IS - 01 SP - E56 EP - E59 DA - 2018/02/21 KW - myasthenia gravis KW - refractory MG KW - immunosuppression KW - rituximab KW - eculizumab AB - Among all patients with myasthenia gravis (MG), 10 to 15% are considered to be refractory to (expanded) standard treatments. Current international consensus guidelines for the management of myasthenia gravis recommend referral of refractory MG patients to centers with expertise in the treatment of MG and chronic intravenous immunoglobulin therapy or plasmapheresis. Here we briefly summarize current approaches to overcome refractory myasthenia gravis. PB - © Georg Thieme Verlag KG DO - 10.1055/s-0043-125342 UR - http://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0043-125342 ER -